Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site

Yu-Chen Lo, Olga Cormier, Tianyun Liu, K.w. Nettles, John A. Katzenellenbogen, Tim Stearns, Russ B. AltmanNature Communications 2019 · DOI

TL;DR

This paper reveals an unexpected structural similarity between the binding pockets of estrogen receptors (ERs) and the taxane-binding site on beta-tubulin. By leveraging this insight, the researchers repurposed selective estrogen receptor modulators (SERMs) as potential microtubule-targeting agents, demonstrating their ability to stabilize microtubules and inhibit cancer cell proliferation through an ER-independent mechanism.

What Problem Does This Paper Address?

Taxanes, a class of potent anticancer drugs like paclitaxel, exert their effects by stabilizing microtubules, essential components of the cell's internal structure and crucial for cell division. However, their clinical use is hampered by severe side effects and the development of drug resistance. The authors sought to discover novel modulators of the taxane-binding site on beta-tubulin to overcome these limitations. Traditional drug repurposing often relies on empirical observations or extensive screening, lacking a clear mechanistic understanding. This study aimed to employ a structure-based approach to identify existing drugs that could be repurposed as microtubule-targeting agents, specifically by looking for molecules that could interact with the taxane binding site.

Methods

The core of this research lies in a computational binding site similarity screen. The authors utilized the PocketFeature algorithm to compare the 3D structure of the beta-tubulin taxane-binding pocket against a database of over 14,000 drug-like protein pockets from the Protein Data Bank (PDB). PocketFeature quantifies similarity by analyzing the microenvironment around residues within a binding site, generating a PocketFeature Score (PFS). A low PFS (<-3.5) indicates a high likelihood of cross-reactivity.

Following the computational screen, promising candidate ligands were identified. These candidates were then subjected to:

  • Computational docking to predict their binding affinity to the taxane site.
  • In vitro tubulin polymerization assays to assess their direct effect on microtubule assembly.
  • In vivo cell-based assays using hTERT-RPE1 human epithelial cells to evaluate their impact on microtubule organization and stability. This included:
  • Nocodazole challenge assays to test microtubule resistance to depolymerization.
  • SiR-Tubulin competition assays to determine if SERMs bind to the taxane site by competing with a fluorescent paclitaxel conjugate.
  • Live-cell imaging to track cell proliferation and death over time.
  • Immunofluorescence microscopy to visualize microtubule and DNA structures.

Datasets

The primary dataset used was the Protein Data Bank (PDB), from which over 14,000 drug-like protein pockets were extracted. The authors also utilized data from the NCI60 cancer cell line screen to assess the antiproliferative effects of selected SERMs across various cancer types and their ER status.

Key Insights and Ideas

  • Unexpected ER-Tubulin Pocket Similarity: The most striking finding is the computational identification of a significant structural similarity between the estrogen receptor (ER) binding pocket and the beta-tubulin taxane-binding pocket. This was entirely unexpected and suggests a potential for cross-reactivity between molecules targeting these seemingly unrelated proteins.
  • SERMs as Microtubule Modulators: The study demonstrates that several Selective Estrogen Receptor Modulators (SERMs), drugs primarily known for their role in hormone therapy, can directly interact with the taxane-binding site on beta-tubulin.
  • ER-Independent Mechanism: Crucially, the research suggests that SERMs can inhibit cancer cell proliferation and induce cell death through a mechanism that does not rely on estrogen receptor signaling. This opens up new therapeutic avenues for ER-negative cancers.
  • Drug Repurposing Power: This work highlights the efficacy of structure-based computational approaches for drug repurposing, enabling the identification of novel therapeutic applications for existing drugs.

Key Results

  • The computational screen identified 53 drug-like pockets with significant similarity to the beta-tubulin taxane site, with estrogen receptors being the most enriched target family (12 out of 53).
  • Nine selected SERMs were evaluated and confirmed to interact with the taxane site, stabilize microtubules, and inhibit cell proliferation.
  • Specific SERMs, such as RAL (7) and TAM analogues (5C6, 5C7), showed strong microtubule stabilization in vitro and in vivo, and some demonstrated displacement of SiR-Tubulin, indicating binding to the taxane site.
  • RAL (7) and LAS (13) significantly reduced cell proliferation with minimal cell death, while TAM analogues like 5C6 (3) and 5C7 (1) were cytotoxic, leading to rapid cell death.
  • The antiproliferative effects of SERMs were observed in both ER-positive and ER-negative cancer cell lines, supporting an ER-independent mechanism.

Limitations and Future Work

  • Affinity Differences: While SERMs can bind to the taxane site, their binding affinity is generally lower than that of paclitaxel. This is attributed to paclitaxel's larger size and structural complexity, allowing for more extensive interactions within the binding pocket.
  • SERM Optimization: The SERMs used in this study are not optimized for microtubule binding. Future work could focus on structure-guided design to improve the affinity and specificity of SERM-tubulin interactions.
  • Mechanism of Cell Death: While SERMs induce cell death, the precise mechanisms for some classes (e.g., RAL) may involve mitotic slippage or other interphase-related processes, requiring further investigation.
  • Clinical Translation: The study suggests that SERMs like RAL and certain TAM analogues could be further explored as potential anticancer agents beyond their current indications, particularly for cancers resistant to traditional taxanes. Further research into their structural features and medicinal chemistry efforts are needed to optimize them for improved efficacy and reduced side effects.

Summary updated

Abstract

Taxanes are a family of natural products with a broad spectrum of anticancer activity. This activity is mediated by interaction with the taxane site of beta-tubulin, leading to microtubule stabilization and cell death. Although widely used in the treatment of breast cancer and other malignancies, existing taxane-based therapies including paclitaxel and the second-generation docetaxel are currently limited by severe adverse effects and dose-limiting toxicity. To discover taxane site modulators, we employ a computational binding site similarity screen of > 14,000 drug-like pockets from PDB, revealing an unexpected similarity between the estrogen receptor and the beta-tubulin taxane binding pocket. Evaluation of nine selective estrogen receptor modulators (SERMs) via cellular and biochemical assays confirms taxane site interaction, microtubule stabilization, and cell proliferation inhibition. Our study demonstrates that SERMs can modulate microtubule assembly and raises the possibility of an estrogen receptor-independent mechanism for inhibiting cell proliferation.
BibTeX
@inproceedings{lo2019pocket,
  author = {Yu-Chen Lo and Olga Cormier and Tianyun Liu and K.W. Nettles and John A. Katzenellenbogen and Tim Stearns and Russ B. Altman},
  title = {{Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site}},
  booktitle = {Nature Communications},
  year = {2019},
  doi = {10.1038/s41467-019-08965-w},
}
Figure